论文部分内容阅读
目的:探讨肝动脉化疗栓塞(TACE)联合三维适形放疗(3DCRT)治疗原发性肝癌(PHC)的临床效果。方法:对经过病理学验证的原发性肝癌188例,随机均分成两组,对观察组进行TACE联合3DCRT治疗,对对照组进行单纯的TACE治疗。结果:全部原发性肝癌患者均完成治疗,检查发现观察组有58例AFP指标下降超过50%,对照组仅28例AFP指标下降超过50%,两组结果具有显著性差异(P<0.01);观察组中1、2、3年生存率分别为80.4%、58.2%、41.3%,对照组为49.6%、23.3%、16.1%,两组结果比较差异有统计学意义(P<0.05);两组毒副作用无明显差异。结论:TACE联合3DCRT治疗原发性肝癌的近期疗效优于单纯TACE治疗,没有不良反应,在综合治疗原发性肝癌的方法中是一种比较理想的方法。
Objective: To investigate the clinical effect of transcatheter arterial chemoembolization (TACE) and three-dimensional conformal radiotherapy (3DCRT) in the treatment of primary hepatocellular carcinoma (PHC). Methods: 188 cases of primary liver cancer confirmed by pathology were randomly divided into two groups. The observation group was treated with TACE combined with 3DCRT and the control group was treated with TACE alone. Results: All the patients with primary hepatocellular carcinoma were treated. The AFP index of 58 cases in the observation group decreased by more than 50%, while in the control group, only 28 cases of AFP index decreased by more than 50%. There was a significant difference between the two groups (P <0.01) The survival rates of one, two and three years in the observation group were 80.4%, 58.2% and 41.3% respectively, and those in the control group were 49.6%, 23.3% and 16.1% respectively. There was significant difference between the two groups (P <0.05). No significant difference between the two groups of side effects. CONCLUSION: TACE combined with 3DCRT is superior to TACE in the treatment of primary liver cancer and has no adverse reactions. It is an ideal method in the comprehensive treatment of primary liver cancer.